Plant extract shows promise in ovarian cancer maintenance trial

NCT ID NCT07495397

Recruiting now Disease control Sponsor: The First Hospital of Jilin University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether daphnetin capsules, made from a daphne plant extract, can improve outcomes when combined with standard chemotherapy (TC regimen) for stage III-IV epithelial ovarian cancer. About 98 participants who had initial surgery will receive the combination, then continue daphnetin with targeted therapy as maintenance. The goal is to see if this approach delays cancer progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: daphnetin capsules (from daphne plant extract)
What this could lead to: If it works, this could provide a new maintenance therapy option to help control advanced ovarian cancer after initial treatment.
What could go wrong: This is an early, single-arm trial with no control group, so results may not be conclusive. Side effects from the combination therapy are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPITHELIAL OVARIAN CANCER

Contacts and locations

Locations

The First Hospital of Jilin University
RECRUITING

Changchun, Jilin, 130000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.